Overview

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic cancer that has relapsed following donor peripheral stem cell transplantation. PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus donor white blood cell infusion in treating patients who have relapsed hematologic cancer following donor peripheral stem cell transplantation.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Maryland Greenebaum Cancer Center
University of Maryland, Baltimore
Treatments:
Cyclophosphamide
Etoposide
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed relapsed or refractory hematologic
malignancy Acute leukemia Myelodysplasia Non-Hodgkin's lymphoma Hodgkin's disease Multiple
myeloma Chronic lymphocytic leukemia Chronic myeloid leukemia Accelerated phase or blast
crisis Chronic phase with failed prior donor lymphocyte infusion No active acute or
extensive chronic graft versus host disease Prior allogeneic stem cell transplant (SCT)
required At least 60 days since prior SCT Nonmyeloablative SCT allowed

PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy:
Greater than 4 weeks Hematopoietic: Not specified Hepatic: Not specified Renal: Not
specified Other: No severe psychiatric illness that may preclude informed consent Fertile
patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics At least 7 days
since prior immunomodulatory medications (e.g., interferon or interleukin-2) Chemotherapy:
Not specified Endocrine therapy: At least 7 days since prior steroids Radiotherapy: Not
specified Surgery: Not specified Other: At least 7 days since prior immunosuppressives
(e.g., cyclosporine, tacrolimus, or mycophenolate mofetil) No concurrent immunosuppressive
medications for graft versus host disease